Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genomics-based drug company Galapagos has entered into a new drug discovery collaboration with AstraZeneca focusing on respiratory and inflammatory drugs.
Subscribe to our email newsletter
Galapagos will collaborate with AstraZeneca via its service division BioFocus DPI. Under the terms of the agreement, BioFocus DPI will perform hit-to-lead medicinal chemistry services for AstraZeneca’s respiratory and inflammatory drug discovery programs. As a result of the alliance, Galapagos is set to receive E650,000.
“We are very pleased with this initial contract to support AstraZeneca in developing novel drugs,” said Onno van de Stolpe, CEO of Galapagos. “Our world-class medicinal chemistry expertise within BioFocus DPI will be of great use in this new collaboration and establish the basis for a potentially long-term relationship.”
“We chose to work with BioFocus DPI because of their reputation and ability in modern lead generation methodologies,” added Dr Lars-Erik Arvidsson, vice president of R&D Lund, AstraZeneca.